BioCentury
ARTICLE | Clinical News

BCI-838: Phase I data

March 12, 2012 7:00 AM UTC

A double-blind, placebo-controlled, Dutch Phase I trial in 31 healthy volunteers showed that single ascending-doses of up to 900 mg oral BCI-838 were well tolerated with no severe adverse events repor...